Granted Patent B2

US 12,746,222 · App. 18/249,022 · Granted Sep 29, 2026

Inventors: Steven Kim (Los Altos, CA); Karun D. Naga (Los Altos, CA); Hanson S. Gifford, III (Woodside, CA); James Su (Newark, CA); Nassireddin Mokarram-Dorri (Campbell, CA); Mark Deem (Portola Valley, CA); Stephen W. Boyd (San Francisco, CA); Koon Kiat Teu (Singapore, SG); Wei Li Lee (Singapore, SG); Darryl Lim Wi Chung (Singapore, SG); Edward D. Gifford (Glastonbury, CT)

Assignee: Foundry Therapeutics, Inc.

A61K31/337A61K9/0024A61K31/015A61P35/00

Abstract

Claims (18)

1 . A method of treating malignant ascites, the method comprising:

placing an implantable depot in a patient's peritoneal cavity, wherein the depot comprises a therapeutic region and a control region covering at least a potion of the therapeutic agent, the therapeutic region comprising a therapeutic agent mixed with a polymer, and wherein the therapeutic agent includes a chemotherapeutic agent;

via the depot, providing sustained release of the therapeutic agent to the peritoneal cavity, wherein

the sustained release causes a greater exposure in the peritoneal cavity to the therapeutic agent over time as compared to exposure resulting from systemic administration of the therapeutic agent.

2 . The method of claim 1 , further comprising administering one or more treatments selected from the group consisting of surgery, ablation, radiation, and systemic drug therapy in conjunction with administering the implantable depot.

3 . The method of claim 2 , wherein the surgery comprises open surgery, laparoscopic surgery, or endoscopic surgery.

4 . The method of claim 2 , wherein the radiation comprises external beam radiation, brachytherapy seed radiation, or sterotactic radiotherapy.

5 . The method of claim 1 , wherein the period of time is at least one month.

6 . The method of claim 1 , wherein the period of time is at least three months.

7 . The method of claim 1 , wherein the period of time is at least six months.

8 . The method of claim 1 , wherein the period of time is at least twelve months.

9 . A method of treating malignant ascites in a peritoneal cavity of a patient, wherein the patient is experiencing one or more symptoms associated with the malignant ascites, the method comprising:

placing an implantable depot in the patient's peritoneal cavity, the depot comprising a therapeutic region and a control region covering at least a portion of a surface of the therapeutic region, wherein the therapeutic region includes a chemotherapeutic agent;

via the implanted depot, providing a sustained release of the chemotherapeutic agent directly to the peritoneal cavity;

administering one or more treatments to the patient, the one or more treatments comprising surgery, radiation, intraperitoneal chemotherapy, and/or systemic drug therapy; and

relieving the one or more symptoms of the patient to a greater extent as compared to a patient who receives the one or more treatments but does not receive the implantable depot, wherein the one or more symptoms comprises anorexia, nausea, vomiting, abdominal pain, abdominal swelling, abdominal distension, and/or dyspnea.

10 . The method of claim 9 , wherein the chemotherapeutic agent is FDA-approved for systemic administration to treat one or more cancers of the human body.

11 . The method of claim 9 , wherein the chemotherapeutic agent is an alkylating agent, an antimetabolite, an anthracycline antibiotic, an antitumor antibiotic, a taxane, a plant alkaloid, an antimicrotubule agent, or any combination thereof.

Assignments (7)

Continuity (2)

References Cited (400)